The New Blueprint for Vaccine Development
March 12, 2026
ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness
5 min read
False
Advertisement
Drug Discovery
Precision Therapies: The Last Mile
By Pete Harbin
March 12, 2026
Why therapies still take years to reach the patients who need them
4 min read
Engineering CAR T Cells to Resist Tumor Immune Suppression
March 9, 2026
CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models
2 min read
Refining CAR-NK Design
March 4, 2026
Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.
1 min read
A Pharmacologic Off-Switch for Split CARs
March 3, 2026
Study describes a venetoclax-regulated off-switch CAR system with dose-dependent control of receptor assembly in vitro and in vivo
2 min read
Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D
February 25, 2026
A Q&A with iXCells Biotechnologies CEO, Steve Smith
8 min read
Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery
February 25, 2026
Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
1 min read
Building Better Oral Suspensions for Pediatric & Real-World Use
February 18, 2026
Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation
4 min read
Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
February 17, 2026
Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS
2 min read
The Role of AI in Rare Disease Drug Discovery
By Dan Williams
February 6, 2026
AI, data-sharing, and gene technologies are peering into the future of rare disease drug development, and overcoming economic, regulatory, and diagnostic challenges for transformative therapies.
9 min read
